Filing Flows › ICU Medical (ICUI) › Guidance & outlook
ICU Medical (ICUI) guidance and outlook
ICU Medical (ICUI) raised its guidance on Nov 5, 2026: Net income $73.0M–$83.0M for FY2026; EPS $2.89–$3.29 for FY2026; EBITDA $415M–$435M for FY2026; EPS $8.60–$9.00 for FY2026. ICU Medical's 10-Q filed Nov 5, 2026 makes 19 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Net income | FY2026 | $73.0M–$83.0M | reaffirmed |
| EPS | FY2026 | $2.89–$3.29 | reaffirmed |
| EBITDA | FY2026 | $415M–$435M | reaffirmed |
| EPS | FY2026 | $8.60–$9.00 | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We do not expect any additional refunds related to tariffs previously paid under IEEPA to be material.
- Based on current geopolitical conditions we expect foreign currency exchange rates, freight costs, oil prices, interest rates, and general inflation to remain subject to volatility in the market.
- Higher fuel prices along with disruptions to transportation routes are expected to result in higher logistics costs and affect our operating results, liquidity, and cash flows, particularly if conditions persist or escalate.
- We will continue to monitor developments and assess potential impacts on our business and financial position.
- We do not expect any additional refunds related to tariffs previously paid under IEEPA to be material and, therefore, do not expect such refunds to materially impact our future gross margins..
- R&D expenses for both periods presented generally include compensation and benefit expenses, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs incurred in our ongoing R&D projects.
- As of September 30, 2026, we expect to pay the majority of our outstanding restructuring charges during the next twelve months.
- We expect restructuring costs to decrease during the remainder of 2026.
- This capital project will be funded by OPF, and we have no commitment to provide cash in connection with the plant expansion.
- Our equity in (losses) earnings of unconsolidated affiliates related to our Otsuka ICU Medical LLC ("OIM") joint venture is expected to be impacted by anticipated non-cash impairment charges related to the write-off of certain historical plant assets and equipment as they are decommissioned or replaced prior to the end of their respective useful lives.
- Further, our equity in (losses) earnings of unconsolidated affiliates may also be impacted by certain expenses incurred solely for the benefit of our joint venture partner that will be fully reimbursable under our contract exit provisions.
- At the date of issuance of this report, our issuer and Term Loan B credit ratings assigned and outlook were as follows:
ICU Medical's latest quarter
ICU Medical, Q3 2026: revenue $560M (+4% year over year), operating margin 9.3%, net earnings $26.8M, operating cash flow $99.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did ICU Medical raise or lower its guidance?
ICU Medical (ICUI) raised its guidance on Nov 5, 2026: Net income $73.0M–$83.0M for FY2026; EPS $2.89–$3.29 for FY2026; EBITDA $415M–$435M for FY2026; EPS $8.60–$9.00 for FY2026.
What does ICU Medical expect?
We do not expect any additional refunds related to tariffs previously paid under IEEPA to be material. Based on current geopolitical conditions we expect foreign currency exchange rates, freight costs, oil prices, interest rates, and general inflation to remain subject to volatility in the market. Higher fuel prices along with disruptions to transportation routes are expected to result in higher logistics costs and affect our operating results, liquidity, and cash flows, particularly if conditions persist or escalate.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.